| Trial ID: | L2502 |
| Source ID: | NCT01484262
|
| Associated Drug: |
Liraglutide
|
| Title: |
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide|DRUG: insulin
|
| Outcome Measures: |
Primary: Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life), At the end of the observational period (52 weeks) | Secondary: Total cost of patient's diseases, At the end of the observational period (52 weeks)|Total cost of patient education, At the end of the observational period (52 weeks)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1344
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2011-11-14
|
| Completion Date: |
2014-10-31
|
| Results First Posted: |
|
| Last Update Posted: |
2018-11-01
|
| Locations: |
Novo Nordisk Investigational Site, Mainz, 55127, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01484262
|
